ICU Medical (ICUI) Stock Overview
Develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
ICUI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
ICU Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$153.49 |
| 52 Week High | US$162.18 |
| 52 Week Low | US$107.00 |
| Beta | 0.76 |
| 1 Month Change | 7.94% |
| 3 Month Change | 21.61% |
| 1 Year Change | 21.35% |
| 3 Year Change | -11.55% |
| 5 Year Change | -21.97% |
| Change since IPO | 3,228.70% |
Recent News & Updates
Narrative Update • Jun 16
ICUI: IV Replacement Cycle And Market Share Gains Will Support Upside
ICU Medical's updated analyst price target of $172.50, only slightly below the prior $172.86, reflects a modest adjustment tied to refined assumptions for long term discount rates, growth, margins and P/E multiples. Analysts highlight potential benefits from IV system replacement demand, limited exposure to higher oil prices, expected tariff and efficiency offsets, and possible future support from share buybacks as leverage declines.Narrative Update • Jun 02
ICUI: IV Replacement Cycle And Margin Resilience Are Expected To Support Upside
Analysts have trimmed their fair value estimate for ICU Medical from about $180.17 to $172.86, citing a recalibrated P/E outlook. They also point to expectations for stronger revenue growth, wider profit margins, and benefits from IV system replacement demand, limited oil exposure, and potential efficiencies and buybacks highlighted in recent research.Recent updates
Narrative Update • Jun 16
ICUI: IV Replacement Cycle And Market Share Gains Will Support Upside
ICU Medical's updated analyst price target of $172.50, only slightly below the prior $172.86, reflects a modest adjustment tied to refined assumptions for long term discount rates, growth, margins and P/E multiples. Analysts highlight potential benefits from IV system replacement demand, limited exposure to higher oil prices, expected tariff and efficiency offsets, and possible future support from share buybacks as leverage declines.Narrative Update • Jun 02
ICUI: IV Replacement Cycle And Margin Resilience Are Expected To Support Upside
Analysts have trimmed their fair value estimate for ICU Medical from about $180.17 to $172.86, citing a recalibrated P/E outlook. They also point to expectations for stronger revenue growth, wider profit margins, and benefits from IV system replacement demand, limited oil exposure, and potential efficiencies and buybacks highlighted in recent research.Analysis Article • May 14
ICU Medical's (NASDAQ:ICUI) Shareholders May Want To Dig Deeper Than Statutory Profit
ICU Medical, Inc. ( NASDAQ:ICUI ) just released a solid earnings report, and the stock displayed some strength. While...Narrative Update • Apr 21
ICUI: Improving Operations And 2026 Guidance Are Expected To Support Upside
ICU Medical's updated analyst price target has edged down roughly $2.50 to about $180, as analysts align their models with slightly lower fair value estimates and modest tweaks to growth, margin, and future P/E assumptions following recent research updates. Analyst Commentary Recent research on ICU Medical reflects a mix of optimism about execution into 2026 and some caution around fair value, which is feeding into the latest price target revisions around the $180 level.Seeking Alpha • Apr 10
ICU Medical Moving Toward A Cleaner Margin Leverage And Capital Return Story
Summary ICU Medical is positioned for margin expansion as Smiths Medical integration and remediation costs subside, with upcoming product launches supporting growth. ICUI is gaining share in infusion pumps and consumables, leveraging product differentiation and rebounding from past compliance issues. Management targets net debt/EBITDA below 2.0x, opening the door for increased capital returns via buybacks or dividends within a couple of years. With shares undervalued relative to a $185 fair value target, patient GARP investors may benefit if margin improvement and execution materialize. Read the full article on Seeking AlphaNarrative Update • Apr 05
ICUI: Improving Operations And 2026 Outlook Are Expected To Support Upside
ICU Medical's analyst price targets have edged higher into a roughly $178 to $180 range, as analysts point to improving operations and updated 2026 guidance that supports slightly higher EBITDA and EPS assumptions. Analyst Commentary Bullish Takeaways Bullish analysts are lifting price targets into the $178 to $180 range, which signals growing confidence that current valuation can be supported by the updated 2026 outlook.Narrative Update • Mar 21
ICUI: Improving Operations And 2026 Earnings Framework Are Expected To Unlock Upside
Analysts have nudged ICU Medical's consensus price target higher into the high $170s to $180 range, citing slightly higher estimates into 2026 and continued improvements in day to day business operations as key supports for the updated view. Analyst Commentary Bullish Takeaways Bullish analysts are lifting price targets into the high $170s to $180 range, signaling more confidence in how current valuation lines up with their updated models.Narrative Update • Mar 07
ICUI: Smoother Execution And 2026 Framework Are Expected To Unlock Upside
Analysts have nudged their average price target for ICU Medical slightly higher to about $180, reflecting updated views that operations are running more smoothly and that 2026 guidance and estimates appear achievable. Analyst Commentary Bullish analysts are modestly lifting their targets into the high $170s and low $180s, pointing to cleaner execution and a 2026 framework that lines up with current Street thinking.Narrative Update • Feb 21
ICUI: Firmer 2026 Outlook And Execution Will Support Upside Potential
Narrative Update: ICU Medical Analyst Price Target Shift The updated analyst fair value estimate for ICU Medical edges up from about $180.83 to $182.67, reflecting slightly higher Street price targets in the $178 to $180 range and analyst views that operations and the forward outlook into 2026 are on a firmer footing. Analyst Commentary Street commentary around ICU Medical has tilted constructive, with recent price target moves clustering in the high $170s to $180 range and linking that view to execution into 2026.Narrative Update • Feb 06
ICUI: Stable Assumptions And Discount Rate Will Support Upside Potential
Analysts have kept their price target on ICU Medical broadly aligned with prior views, with only a minor adjustment based on slightly updated assumptions for discount rate, revenue growth, profit margin, and future P/E that together support a fair value estimate of about $180.83 per share. Valuation Changes Fair Value: The fair value estimate is unchanged at about US$180.83 per share.Narrative Update • Jan 21
ICUI: Narrowed 2025 Loss Guidance Will Support Potential Upside Ahead
Analysts kept their price target for ICU Medical broadly steady around US$181, with only small model tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions driving this narrative update. What's in the News ICU Medical updated fiscal 2025 guidance, now estimating GAAP net loss in a range of US$8 million to US$0 instead of the prior range of US$43 million to US$35 million.Analysis Article • Jan 16
Why ICU Medical, Inc. (NASDAQ:ICUI) Could Be Worth Watching
While ICU Medical, Inc. ( NASDAQ:ICUI ) might not have the largest market cap around , it saw a significant share price...Narrative Update • Jan 06
ICUI: Narrowing 2025 Loss Guidance Will Support Future Share Performance
Analysts are keeping their price target for ICU Medical broadly steady at about US$181, with only small tweaks to inputs like the discount rate, revenue growth, profit margin, and future P/E assumptions to reflect updated risk and return expectations. What's in the News ICU Medical updated its earnings guidance for fiscal year 2025, revising projected GAAP net loss from a range of US$43 million to US$35 million to a range of US$8 million to US$0, and GAAP diluted loss per share from a range of US$1.68 to US$1.38 to a range of US$0.30 to US$0.00 (Key Developments).Narrative Update • Dec 15
ICUI: Improved Earnings Outlook Will Drive Future Share Performance
Analysts have nudged their price target for ICU Medical slightly higher to approximately $181 per share, up from about $181 previously. This reflects modestly lower discount rate assumptions and steady expectations for long term revenue growth, margins, and valuation multiples.Narrative Update • Dec 01
ICUI: Portfolio Transformation Will Drive Share Performance Following Recent Joint Venture
ICU Medical’s analyst price target has been raised by $8 to $153, as analysts cite ongoing portfolio transformation and strategic business moves as key drivers for improved valuation. Analyst Commentary Recent analyst discussions have focused on ICU Medical's ongoing portfolio transformation and its potential impacts on company performance.Analysis Article • Nov 28
ICU Medical, Inc.'s (NASDAQ:ICUI) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
ICU Medical, Inc. ( NASDAQ:ICUI ) shares have had a really impressive month, gaining 27% after a shaky period...Narrative Update • Nov 17
ICUI: Vital Care Portfolio Moves Will Unlock Greater Shareholder Value
ICU Medical’s fair value estimate has been revised upward from $176.50 to $180.83 per share. This change reflects analysts’ increased optimism on growth and profitability following recent portfolio transformations and ongoing strategic evaluations.Narrative Update • Aug 27
Infusion Therapies And Advanced Systems Will Shape Healthcare Outcomes
The reduction in ICU Medical’s price target reflects weaker growth expectations, as consensus revenue projections have turned negative, while a lower future P/E ratio suggests diminished earnings optimism; accordingly, the fair value estimate has decreased from $182.80 to $176.50. What's in the News ICU Medical raised its 2025 GAAP net loss guidance, now expecting a loss between $43 million and $35 million, with GAAP diluted loss per share between $1.68 and $1.38.Analysis Article • Aug 25
ICU Medical, Inc. (NASDAQ:ICUI) Shares Could Be 46% Below Their Intrinsic Value Estimate
Key Insights The projected fair value for ICU Medical is US$238 based on 2 Stage Free Cash Flow to Equity ICU Medical's...Analysis Article • Jul 06
ICU Medical, Inc.'s (NASDAQ:ICUI) Price Is Right But Growth Is Lacking
ICU Medical, Inc.'s ( NASDAQ:ICUI ) price-to-sales (or "P/S") ratio of 1.4x might make it look like a buy right now...New Narrative • May 26
Aging Populations And Emerging Markets Will Expand Hospital Care
Demographic trends and rising healthcare spending are driving strong demand, supporting growth across key business segments and expanding ICU Medical's addressable market.Analysis Article • May 11
ICU Medical, Inc. (NASDAQ:ICUI) Just Reported And Analysts Have Been Cutting Their Estimates
Shareholders might have noticed that ICU Medical, Inc. ( NASDAQ:ICUI ) filed its quarterly result this time last week...Analysis Article • Mar 19
ICU Medical, Inc.'s (NASDAQ:ICUI) Shares Lagging The Industry But So Is The Business
You may think that with a price-to-sales (or "P/S") ratio of 1.5x ICU Medical, Inc. ( NASDAQ:ICUI ) is a stock worth...Analysis Article • Feb 21
ICU Medical (NASDAQ:ICUI) Has A Somewhat Strained Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Seeking Alpha • Jan 02
ICU Medical: What's Ahead In 2025
Summary ICU Medical, Inc. shares surged over 50% in 2024 despite a decline in profits, with a sharp earnings rebound projected for FY2025. The company is forming a joint venture with Japan’s Otsuka creating one of the largest IV solutions manufacturing networks on the globe. ICU Medical does have a significant amount of debt and there has been consistent insider selling in the stock. Can the shares keep their upward momentum in 2025? An analysis follows in the paragraphs below. Read the full article on Seeking AlphaAnalysis Article • Dec 06
ICU Medical, Inc.'s (NASDAQ:ICUI) Shares Lagging The Industry But So Is The Business
You may think that with a price-to-sales (or "P/S") ratio of 1.6x ICU Medical, Inc. ( NASDAQ:ICUI ) is a stock worth...Analysis Article • Nov 15
ICU Medical, Inc. (NASDAQ:ICUI) Just Reported And Analysts Have Been Lifting Their Price Targets
ICU Medical, Inc. ( NASDAQ:ICUI ) shareholders are probably feeling a little disappointed, since its shares fell 3.7...Analysis Article • Oct 01
A Look At The Intrinsic Value Of ICU Medical, Inc. (NASDAQ:ICUI)
Key Insights The projected fair value for ICU Medical is US$188 based on 2 Stage Free Cash Flow to Equity Current share...Analysis Article • Aug 18
ICU Medical, Inc.'s (NASDAQ:ICUI) Shares Bounce 30% But Its Business Still Trails The Industry
ICU Medical, Inc. ( NASDAQ:ICUI ) shares have continued their recent momentum with a 30% gain in the last month alone...Analysis Article • Aug 07
ICU Medical (NASDAQ:ICUI) Seems To Use Debt Quite Sensibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Jun 27
ICU Medical - Stabilization Is In Sight, But The Road Back Is Difficult
Summary ICU Medical has continued to struggle to grow since its acquisition of Smiths Medical, with management attention and resources focused on remediation and improvement instead of growth. The remediation and integration process should be nearing the finish line, leaving management free to refocus around rebuilding market share in its core infusion markets and driving innovation and leverage. As manufacturing leverage normalizes and reaccelerates, low-to-mid single-digit revenue growth should drive EBITDA margins from the mid-teens to the high-teens, with free cash flow following. ICU Medical shares do look undervalued, but valuation of slow-growing small-cap medical device companies is tricky, and I'd prefer to see more evidence of stabilization and reacceleration. Read the full article on Seeking AlphaAnalysis Article • Jun 23
ICU Medical, Inc.'s (NASDAQ:ICUI) Intrinsic Value Is Potentially 34% Above Its Share Price
Key Insights The projected fair value for ICU Medical is US$155 based on 2 Stage Free Cash Flow to Equity ICU Medical's...Analysis Article • May 09
Shareholders May Be Wary Of Increasing ICU Medical, Inc.'s (NASDAQ:ICUI) CEO Compensation Package
Key Insights ICU Medical will host its Annual General Meeting on 15th of May Total pay for CEO Vivek Jain includes...Shareholder Returns
| ICUI | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -1.2% | -1.7% | -0.9% |
| 1Y | 21.3% | -18.9% | 19.4% |
Return vs Industry: ICUI exceeded the US Medical Equipment industry which returned -18.9% over the past year.
Return vs Market: ICUI exceeded the US Market which returned 19.4% over the past year.
Price Volatility
| ICUI volatility | |
|---|---|
| ICUI Average Weekly Movement | 5.1% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ICUI has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ICUI's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 13,000 | Vivek Jain | www.icumed.com |
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options.
ICU Medical, Inc. Fundamentals Summary
| ICUI fundamental statistics | |
|---|---|
| Market cap | US$3.94b |
| Earnings (TTM) | US$46.34m |
| Revenue (TTM) | US$2.16b |
82.8x
P/E Ratio1.8x
P/S RatioIs ICUI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ICUI income statement (TTM) | |
|---|---|
| Revenue | US$2.16b |
| Cost of Revenue | US$1.34b |
| Gross Profit | US$818.16m |
| Other Expenses | US$771.82m |
| Earnings | US$46.34m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.85 |
| Gross Margin | 37.93% |
| Net Profit Margin | 2.15% |
| Debt/Equity Ratio | 60.7% |
How did ICUI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/14 21:36 |
| End of Day Share Price | 2026/07/14 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ICU Medical, Inc. is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Terwilliger | Benchmark Company |
| Sam Eiber | BTIG |
| Lawrence Solow | CJS Securities, Inc. |